Releases
DRRX
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest DURECT (DRRX) stock and general news. This information may help you make smarter investment decisions.
About DRRX
DURECT Corporation is a biopharmaceutical company focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. DUR‑928 is a candidate in its Epigenetic Regulator Program. Injectable DUR-928 is under testing in a Phase II clinical trial and oral DUR-928 is under testing in a Phase I clinical trial. The chronic toxicity of DUR-928 was further assessed in a 6-month oral study in rats and in a 9-month oral study in dogs. POSIMIR enabling continuous sustained delivery of bupivacaine, a non-opioid local analgesic, over 3 days in adults to control post-surgical pain of patients.